Cyclophosphamide
Cytoxan · Oxazaphosphorine alkylator
Vasopressin-independent hyponatremia; hemorrhagic cystitis.
SIADHCYST
MildOpen →
Alkylating agent (nitrogen mustard)
Chlorambucil
Leukeran · CLB
Oral aromatic nitrogen-mustard alkylator with minimal direct nephrotoxicity; the notable renal-relevant effect is rare drug-associated SIADH/hyponatremia.
Mildearly-cytotoxic · approved 1957
Chronic lymphocytic leukemiaIndolent non-Hodgkin lymphomaWaldenstrom macroglobulinemiaAdvanced Hodgkin lymphoma (historical)
Signature kidney injury
SIADH / Hyponatremia
Chlorambucil has minimal direct nephrotoxicity. Drug-associated SIADH with hyponatremia is reported only rarely, in isolated case reports; tumor lysis is uncommon given its indolent-disease indications and gradual cytoreduction. No reliable incidence figure exists.
Source: Wagner et al., Ann Hematol 1999 (case-level SIADH); incidence not quantified
Mechanism of kidney injury
No characteristic tubular or glomerular toxin. The renal-relevant signal is the syndrome of inappropriate antidiuresis: certain alkylating agents, including chlorambucil, have been linked to inappropriate ADH effect with water retention and dilutional hyponatremia. Because chlorambucil treats indolent malignancies with slow tumor turnover, clinically significant tumor lysis is unusual.
Clinical presentation
When SIADH occurs: euvolemic hyponatremia with low serum osmolality, inappropriately concentrated urine and elevated urine sodium, sometimes with nausea, confusion or seizures if severe and rapid. Otherwise kidney function typically remains stable on therapy.
Onset
Hyponatremia, when reported, has occurred during ongoing dosing, including with low doses; timing is variable.
Reversibility
Reversible
Anticancer mechanism
Aromatic nitrogen-mustard alkylating agent that forms reactive ethyleniminium intermediates and crosslinks DNA, impairing replication and transcription in proliferating lymphoid cells and inducing apoptosis.
Management
Manage drug-associated SIADH per standard hyponatremia principles: free-water restriction, treat severe/symptomatic cases with hypertonic saline using controlled correction rates, and reassess/withhold the offending agent. Direct nephrotoxicity management is rarely needed.
Risk factors
- Concurrent medications or conditions that promote SIADH
- Excess free-water intake
- Older age and reduced renal free-water clearance
- Higher tumor burden (for the uncommon TLS scenario)
Prevention
- Periodic serum sodium monitoring on therapy
- Avoid excessive hypotonic fluid intake
- Standard TLS precautions only if treating bulkier disease
Note · Long-term alkylator exposure carries secondary-malignancy risk; this is a general chlorambucil safety consideration rather than a renal one.
Clinical depth
Renal dose adjustment
No formal renal dose-adjustment scheme is established; chlorambucil is extensively hepatically metabolized to phenylacetic acid mustard with limited unchanged renal excretion. Dosing is guided mainly by hematologic tolerance.
Dialyzability & ESKD dosing
Not characterized as dialyzable and unlikely to be efficiently removed given rapid metabolism and protein binding; dialysis is not used for drug clearance.
Differential diagnosis
Distinguish chlorambucil-associated SIADH from hyponatremia due to other drugs, CNS involvement by lymphoma/leukemia, adrenal insufficiency, hypothyroidism, or volume depletion. Causality for chlorambucil is presumptive and based on case reports.
Monitoring
- Serum sodium and osmolality if hyponatremia is suspected
- CBC (dose-limiting myelosuppression)
- Serum creatinine and electrolytes periodically
- Volume status if hyponatremic
Key trials & series
- CLL frontline trials establishing chlorambucil as a standard oral alkylator (e.g., chlorambucil-based comparator arms); renal/electrolyte events reported only sporadically
Clinical pearls
- Check the sodium, not just the creatinine: the kidney-relevant chlorambucil signal is SIADH/hyponatremia rather than AKI.
- Direct nephrotoxicity from chlorambucil is minimal, and TLS is uncommon because it treats indolent, slowly proliferating disease.
- Reported SIADH has occurred even at low doses, so symptomatic hyponatremia warrants reviewing the drug list.
Where it strikes
Nephron segments
Distal Tubule / Collecting Duct
Fine-tuning of Na, K, Mg, acid & water
Injury signatures
SIADH / HyponatremiaElectrolyte Wasting
Beyond the kidney
Class-level context for the major non-renal toxicities of alkylating agent (nitrogen mustard)s.
Ophthalmic
Keratopathy, uveitis, retinopathy
- Visual disturbance (crizotinib)
Hepatic / Liver
Transaminitis, hepatitis, VOD/SOS
- Transaminitis
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
- CNS effects (lorlatinib)
Evidence
3 peer-reviewed references. Citation metadata via PubMed / NLM.
PMIDChlorambucil-induced inappropriate antidiuresis in a man with chronic lymphocytic leukemia.Wagner AM et al. · Ann Hematol 1999 · PMID 10037268Case report of SIADH attributed to low-dose chlorambucil in CLL without CNS involvement, the principal renal-relevant association for this drug.LandmarkConventional Chemotherapy Nephrotoxicity.Gupta S et al. · Adv Chronic Kidney Dis 2021 · PMID 35190107Onconephrology review addressing chemotherapy-associated electrolyte disturbances including hyponatremia and the generally low direct nephrotoxicity of oral alkylators.LandmarkAcute Kidney Injury in Patients with Cancer.Rosner MH et al. · N Engl J Med 2017 · PMID 28467867Review of AKI and electrolyte/water-balance disturbances in patients with cancer, providing context for chemotherapy-associated SIADH.